Drug sponsors and research institutions face a 30 October 2026 deadline to apply as pairs for the FDA Expedited IND Pilot, a program intended to shorten the path from early drug development work to first in human trials in the United States. The Food and Drug Administration opened applications on 15 September 2026 and said it will select an initial cohort of eight to 10 sponsor and qualified research institution pairs. The agency expects to select and notify that cohort by 18 December 2026, although it said the timeline may vary with application volume.
The Expedited IND Pilot sits inside Operation TrialBlazer, a Department of Health and Human Services initiative launched in June 2026 to reverse the move of early phase clinical research overseas. The FDA said first in human development in the United States can take up to two years, with comparable trials moving more quickly in Australia and China. The pilot tests whether a different way of preparing an application can close part of that gap.
How the Expedited IND Pilot changes the review
Under the usual model, a sponsor submits a complete investigational new drug application before FDA review begins. Under the Expedited IND Pilot, the sponsor works with a qualified research institution, and the agency reviews and accepts individual components on a rolling basis during the pre-IND phase, rather than waiting for a full package. Selected institutions are expected to bring specialised scientific expertise, including nonclinical, clinical and chemistry, manufacturing and controls support.
The Expedited IND Pilot also encourages parallel work during application development, such as institutional review board review and clinical trial site activation, so those steps do not have to wait until the application is complete. By spotting and resolving deficiencies in real time, the program is intended to reduce the risk of a clinical hold during the standard 30 day IND review period. The FDA said sponsors may save six to 12 months compared with current IND submissions.
The FDA retains full regulatory authority throughout, including clinical holds and whether an investigation may proceed. Participation is voluntary, and the Expedited IND Pilot does not modify the statutory or regulatory standards for IND review, safe to proceed determinations, or clinical trial conduct. A sponsor may apply for a single IND program, and may apply with only one designated qualified research institution, although it may continue to work separately with other contract research or manufacturing organisations.
Who can apply to the Expedited IND Pilot
Sponsors and prospective qualified research institutions apply as a pair, with the sponsor submitting the program application. Eligible programs must target a Phase 1 first in human submission reviewed by the Center for Drug Evaluation and Research Office of New Drugs, the Center for Biologics Evaluation and Research Office of Therapeutic Products, or the Oncology Center of Excellence. The small first cohort means the program will reach only a small fraction of sponsors with qualifying programs in this cycle.
Acting FDA Commissioner Kyle Diamantas said in the September announcement: “The pilot not only pairs industry innovators with top research institutions to accelerate high-quality data being submitted to the FDA, it also tests if the partnership can accelerate what happens after the FDA allows a clinical trial to proceed.” He added that the agency will continue implementing Operation TrialBlazer without compromising patient safety.
Operation TrialBlazer extends beyond the FDA pilot. It includes National Institutes of Health work on well powered trials using artificial intelligence, human cell based models and real world data, rare disease work by the National Center for Advancing Translational Sciences, and National Cancer Institute efforts to streamline cancer trial activation and enrolment. A separate fee proposal would cut new drug application fees by 50 percent for submissions including data from at least one Phase 1 trial conducted in the United States after 1 October 2027.
What the Expedited IND Pilot will test
The FDA has said the Expedited IND Pilot will generate evidence for future early stage approaches, including a possible formal accreditation model recognising institutions with strong scientific and regulatory judgment. For now, the Expedited IND Pilot is a test, and its value will be judged on whether paired teams move faster to first in human studies and whether fewer applications run into holds.
Other modernisation efforts are running at the same time. The FDA launched its PreCheck Pilot in February 2026 for domestic manufacturing facilities, selecting seven initial participants in June, while China introduced its PIONEER Program in August 2026 for cell and gene therapy development.
For sponsors still weighing an application, the decision is narrow: find a qualified research institution partner, submit as a pair by 30 October 2026, and wait for the December selection. With eight to 10 pairs planned, most applicants will not be selected in this round.